172 related articles for article (PubMed ID: 32407269)
1. Pharmacogenetic Evaluation of Metformin and Sulphonylurea Response in Mexican Mestizos with Type 2 Diabetes.
Marta M; Sánchez-Pozos K; Jaimes-Santoyo J; Monroy-Escutia J; Rivera-Santiago C; de Los Ángeles Granados-Silvestre M; Ortiz-López MG
Curr Drug Metab; 2020; 21(4):291-300. PubMed ID: 32407269
[TBL] [Abstract][Full Text] [Related]
2. Variants in Pharmacokinetic Transporters and Glycemic Response to Metformin: A Metgen Meta-Analysis.
Dujic T; Zhou K; Yee SW; van Leeuwen N; de Keyser CE; Javorský M; Goswami S; Zaharenko L; Hougaard Christensen MM; Out M; Tavendale R; Kubo M; Hedderson MM; van der Heijden AA; Klimčáková L; Pirags V; Kooy A; Brøsen K; Klovins J; Semiz S; Tkáč I; Stricker BH; Palmer C; 't Hart LM; Giacomini KM; Pearson ER
Clin Pharmacol Ther; 2017 Jun; 101(6):763-772. PubMed ID: 27859023
[TBL] [Abstract][Full Text] [Related]
3. Population diversity of three variants of the SLC47A2 gene (MATE2-K transporter) in Mexican Mestizos and Native Americans.
Favela-Mendoza AF; Fricke-Galindo I; Cuevas-Sánchez WF; Aguilar-Velázquez JA; Martínez-Cortés G; Rangel-Villalobos H
Mol Biol Rep; 2021 Sep; 48(9):6343-6348. PubMed ID: 34383246
[TBL] [Abstract][Full Text] [Related]
4. Altered Glycemic Control Associated With Polymorphisms in the SLC22A1 (OCT1) Gene in a Mexican Population With Type 2 Diabetes Mellitus Treated With Metformin: A Cohort Study.
Reséndiz-Abarca CA; Flores-Alfaro E; Suárez-Sánchez F; Cruz M; Valladares-Salgado A; Del Carmen Alarcón-Romero L; Vázquez-Moreno MA; Wacher-Rodarte NA; Gómez-Zamudio JH
J Clin Pharmacol; 2019 Oct; 59(10):1384-1390. PubMed ID: 31012983
[TBL] [Abstract][Full Text] [Related]
5. Impact of
Ortega-Ayala A; De Andrés F; Llerena A; Bartolo-Montiel CM; Molina-Guarneros JA
Biomed Rep; 2024 Aug; 21(2):117. PubMed ID: 38938740
[TBL] [Abstract][Full Text] [Related]
6. Lack of effect of the SLC47A1 and SLC47A2 gene polymorphisms on the glycemic response to metformin in type 2 diabetes mellitus patients.
Raj GM; Mathaiyan J; Wyawahare M; Priyadarshini R
Drug Metab Pers Ther; 2018 Dec; 33(4):175-185. PubMed ID: 30433870
[TBL] [Abstract][Full Text] [Related]
7. Genetic polymorphisms of organic cation transporter 1 (OCT1) and responses to metformin therapy in individuals with type 2 diabetes: A systematic review.
Mofo Mato EP; Guewo-Fokeng M; Essop MF; Owira PMO
Medicine (Baltimore); 2018 Jul; 97(27):e11349. PubMed ID: 29979413
[TBL] [Abstract][Full Text] [Related]
8. Interaction between polymorphisms in the OCT1 and MATE1 transporter and metformin response.
Becker ML; Visser LE; van Schaik RH; Hofman A; Uitterlinden AG; Stricker BH
Pharmacogenet Genomics; 2010 Jan; 20(1):38-44. PubMed ID: 19898263
[TBL] [Abstract][Full Text] [Related]
9. Genetic polymorphisms potentially associated with response to metformin in postmenopausal diabetics suffering and not suffering with cancer.
Berstein LM; Iyevleva AG; Vasilyev D; Poroshina TE; Imyanitov EN
Cell Cycle; 2013 Dec; 12(23):3681-8. PubMed ID: 24145224
[TBL] [Abstract][Full Text] [Related]
10. Association of genetic variation in the organic cation transporters OCT1, OCT2 and multidrug and toxin extrusion 1 transporter protein genes with the gastrointestinal side effects and lower BMI in metformin-treated type 2 diabetes patients.
Tarasova L; Kalnina I; Geldnere K; Bumbure A; Ritenberga R; Nikitina-Zake L; Fridmanis D; Vaivade I; Pirags V; Klovins J
Pharmacogenet Genomics; 2012 Sep; 22(9):659-66. PubMed ID: 22735389
[TBL] [Abstract][Full Text] [Related]
11. Genetic variants of OCT1 influence glycemic response to metformin in Han Chinese patients with type-2 diabetes mellitus in Shanghai.
Zhou Y; Ye W; Wang Y; Jiang Z; Meng X; Xiao Q; Zhao Q; Yan J
Int J Clin Exp Pathol; 2015; 8(8):9533-42. PubMed ID: 26464716
[TBL] [Abstract][Full Text] [Related]
12. Identification of clinical and pharmacogenetic factors influencing metformin response in Type 2 diabetes mellitus.
Pérez-Gómez N; Fernández-Ortega MD; Elizari-Roncal M; Santos-Mazo E; la Maza-Pereg L; Calvo S; Alcaraz R; Sanz-Solas A; Vinuesa R; Saiz-Rodríguez M
Pharmacogenomics; 2023 Aug; 24(12):651-663. PubMed ID: 37610884
[TBL] [Abstract][Full Text] [Related]
13. Association between organic cation transporter genetic polymorphisms and metformin response and intolerance in T2DM individuals: a systematic review and meta-analysis.
Peng A; Gong C; Xu Y; Liang X; Chen X; Hong W; Yan J
Front Public Health; 2023; 11():1183879. PubMed ID: 37546319
[TBL] [Abstract][Full Text] [Related]
14. Implication of critical pharmacokinetic gene variants on therapeutic response to metformin in Type 2 diabetes.
Phani NM; Vohra M; Kakar A; Adhikari P; Nagri SK; D'Souza SC; Umakanth S; Satyamoorthy K; Rai PS
Pharmacogenomics; 2018 Jul; 19(11):905-911. PubMed ID: 29914345
[TBL] [Abstract][Full Text] [Related]
15. CYP2C9*3 gene variant contributes independently to glycaemic control in patients with type 2 diabetes treated with glibenclamide.
Castelán-Martínez OD; Hoyo-Vadillo C; Bazán-Soto TB; Cruz M; Tesoro-Cruz E; Valladares-Salgado A
J Clin Pharm Ther; 2018 Dec; 43(6):768-774. PubMed ID: 29802808
[TBL] [Abstract][Full Text] [Related]
16. Influence of SLC22A1 rs622342 genetic polymorphism on metformin response in South Indian type 2 diabetes mellitus patients.
Umamaheswaran G; Praveen RG; Damodaran SE; Das AK; Adithan C
Clin Exp Med; 2015 Nov; 15(4):511-7. PubMed ID: 25492374
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenomic association between a variant in SLC47A1 gene and therapeutic response to metformin in type 2 diabetes.
Tkáč I; Klimčáková L; Javorský M; Fabianová M; Schroner Z; Hermanová H; Babjaková E; Tkáčová R
Diabetes Obes Metab; 2013 Feb; 15(2):189-91. PubMed ID: 22882994
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenetics of Metformin Transporters Suggests No Association with Therapeutic Inefficacy among Diabetes Type 2 Mexican Patients.
Ortega-Ayala A; Rodríguez-Rivera NS; Andrés F; LLerena A; Pérez-Silva E; Espinosa-Sánchez AG; Molina-Guarneros JA
Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890074
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the suitability of 19 pharmacogenomics biomarkers for individualized metformin therapy for type 2 diabetes patients.
Xhakaza L; Abrahams-October Z; Pearce B; Masilela CM; Adeniyi OV; Johnson R; Ongole JJ; Benjeddou M
Drug Metab Pers Ther; 2020 Jun; 35(2):. PubMed ID: 32681778
[TBL] [Abstract][Full Text] [Related]
20. Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin.
Shikata E; Yamamoto R; Takane H; Shigemasa C; Ikeda T; Otsubo K; Ieiri I
J Hum Genet; 2007; 52(2):117-122. PubMed ID: 17111267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
